Helius Pons Therapy Shows Positive Gait Improvement in MS Patients
Helius Medical Technologies announced positive results from their PoNSTEP study, demonstrating the long-term benefits of PoNS Therapy for gait...
Jon Napitupulu
Coherus’ Final Phase 2 Combination Data for Metastatic HCC at ASCO-GI 2025
Coherus BioSciences announced final data from its Phase 2 trial of casdozokitug (casdozo), an IL-27-targeting antibody, combined with atezolizumab...
Allurion Gets New US Patent for Next-Gen Weight Loss Device
Allurion Technologies received a patent for its enhanced, next-generation gastric balloon technology, specifically for its improved valve system. This...
Kiromic Biopharma Sees Tumor Volume Decrease in Two Deltacel-01 Patients
Kiromic BioPharma announced positive efficacy results from its Deltacel-01 Phase 1 clinical trial of Deltacel™, an allogeneic, off-the-shelf Gamma...
Nikang’s NKT2152 Dosed in First HCC Patient: Phase 1b/2 Trial Begins
NiKang Therapeutics has initiated a global Phase 1b/2 clinical trial evaluating NKT2152, an oral HIF2α inhibitor, in combination with...
Xilio Announces Phase 2 Data for Vilastobart in Metastatic Colorectal Cancer
Xilio Therapeutics announced initial positive Phase 2 data for vilastobart (XTX101), a tumor-activated anti-CTLA-4 antibody, combined with atezolizumab (Tecentriq®)...
ACTG Launches Second HIV Cure Trial in Africa
The AIDS Clinical Trials Group (ACTG) launched the ACACIA study, a Phase 2 trial investigating the use of two...
RS Biotherapeutics Sees Positive Effects of Lead Compound on Human Lung Tissue
RS BioTherapeutics announced positive results from a human lung tissue study of its lead compound, RSBT-001. The study showed...
Nacuity Gets FDA Fast Track for Retinitis Pigmentosa Treatment
Nacuity Pharmaceuticals has received FDA Fast Track designation for NPI-001, an investigational treatment for retinitis pigmentosa (RP). This designation...
Ropidoxuridine Shows Promise in Glioblastoma Trial
Shuttle Pharmaceuticals has reached 25% enrollment in the initial randomized portion of its Phase 2 clinical trial for Ropidoxuridine...